Multiple myeloma - management
myeloma mgmt · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A clonal plasma cell malignancy causing the CRAB features (hypercalcaemia, renal impairment, anaemia, bone lesions). Modern therapy combines proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibodies, with transplant in fit patients, achieving deep durable responses.
Figures & algorithms
Red flags
- Spinal cord compression
- Severe hypercalcaemia
- Acute kidney injury / cast nephropathy
- Hyperviscosity (visual, neurological change)
- Febrile neutropenia
Assessment
Differential diagnosis
- MGUS / smouldering myeloma
- Waldenstrom macroglobulinaemia
- AL amyloidosis
- Metastatic bone disease
- Other causes of renal failure/hypercalcaemia
- Plasmacytoma
Investigations
- Serum/urine protein electrophoresis and immunofixation, serum free light chains
- FBC, calcium, renal function, albumin, beta-2 microglobulin, LDH
- Bone marrow aspirate/trephine with plasma cell percentage, FISH cytogenetics
- Whole-body MRI or low-dose CT/PET for lytic lesions
- Serum viscosity if symptoms
- Assessment for amyloid if suspected
Management
- Confirm diagnosis using clonal plasma cells plus myeloma-defining events (CRAB or biomarkers)
- Risk-stratify with ISS/R-ISS and cytogenetics
- Treat emergencies first: hypercalcaemia, renal failure, cord compression, hyperviscosity
- Assess transplant eligibility by age, fitness and comorbidity
- Give induction with a triplet/quadruplet (e.g. daratumumab-bortezomib-lenalidomide-dexamethasone)
- Proceed to autologous stem cell transplant in eligible patients, then lenalidomide maintenance
- For transplant-ineligible patients give continuous novel-agent combinations
- Provide bone protection with a bisphosphonate and treat/ prevent skeletal events
- Give thromboprophylaxis with immunomodulatory drugs and antiviral prophylaxis with proteasome inhibitors/daratumumab
- Manage relapse with alternative-class combinations, and consider CAR-T or bispecific antibodies in later lines
Drugs & doses
Bortezomib 1.3 mg/m2 SC weekly + lenalidomide 25 mg PO days 1-21 + dexamethasone 40 mg weekly (VRd backbone)
Daratumumab 1800 mg SC per schedule (added as quadruplet)
Lenalidomide 10-15 mg PO daily maintenance post-transplant
Zoledronic acid 4 mg IV every 3-4 weeks (bone protection; adjust for renal function)
Disposition
Haematology-led management; emergency admission for CRAB emergencies; ongoing outpatient therapy and transplant referral.
Complications & pitfalls
- Renal failure (cast nephropathy)
- Skeletal events and fractures
- Infection/immunoparesis
- Peripheral neuropathy (bortezomib)
- Venous thrombosis (immunomodulatory drugs)
- Secondary malignancy
Exam pearls
- Daratumumab-based quadruplets are now standard first-line induction in many settings
- Protect bones with bisphosphonates in all patients needing therapy
- Immunomodulatory drugs mandate thromboprophylaxis
- Autologous transplant deepens response in fit patients
- Rising free light chains often herald relapse before organ damage
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.
